8/7/2009

The U.S. Navy has awarded two contracts worth $4 million to Entegrion for the development of blood-derived products. The first contract is for the development of Stasix, a powder containing dehydrated particles taken from human blood platelets that can be easily rehydrated and administered to halt a person's internal or external bleeding. The second is for the development of the firm's Resusix, a dehydrated human plasma product with decreased pathogens that is designed for infusion in patients to increase blood volume, treat blood clotting inconsistencies and stop bleeding.

Related Summaries